MX2009008338A - Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. - Google Patents
Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.Info
- Publication number
- MX2009008338A MX2009008338A MX2009008338A MX2009008338A MX2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A MX 2009008338 A MX2009008338 A MX 2009008338A
- Authority
- MX
- Mexico
- Prior art keywords
- conditions
- sodium channel
- mediated diseases
- compounds useful
- treating sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se refiere a compuestos de piridopirimidinona de la fórmula (I): (ver fórmula I) en donde n, R1, R2 y R3 son como se definen en la presente, como uno de sus estereoisómeros, enantiómeros, tautómeros, o una de sus mezclas; o una de sus sales, solvatos o profármacos farmacéuticamente aceptables, de utilidad para el tratamiento y/o de la prevención de enfermedades o condiciones patológicas mediadas por el canal de sodio, como dolor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88825307P | 2007-02-05 | 2007-02-05 | |
US91212207P | 2007-04-16 | 2007-04-16 | |
PCT/US2008/053075 WO2008097991A1 (en) | 2007-02-05 | 2008-02-05 | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009008338A true MX2009008338A (es) | 2009-08-12 |
Family
ID=39420569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009008338A MX2009008338A (es) | 2007-02-05 | 2008-02-05 | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080194616A1 (es) |
EP (1) | EP2079737A1 (es) |
JP (1) | JP2010518026A (es) |
AR (1) | AR065194A1 (es) |
AU (1) | AU2008213836A1 (es) |
BR (1) | BRPI0807351A2 (es) |
CA (1) | CA2677493A1 (es) |
CL (1) | CL2008000369A1 (es) |
MX (1) | MX2009008338A (es) |
RU (1) | RU2009133336A (es) |
TW (1) | TW200838539A (es) |
WO (1) | WO2008097991A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2394984T3 (es) * | 2006-12-18 | 2013-02-07 | Cardoz Ab | Nueva combinación para uso en el tratamiento de trastornos inflamatorios |
ATE543501T1 (de) * | 2006-12-20 | 2012-02-15 | Cardoz Ab | Kombination von pemirolast und ramatroban zur verwendung bei der behandlung von entzündlichen erkrankungen |
EP2229388A4 (en) * | 2008-01-11 | 2012-03-07 | Glenmark Pharmaceuticals Sa | CONDENSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS |
CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
AU2009235276A1 (en) * | 2008-04-07 | 2009-10-15 | Cardoz Ab | New combination for use in the treatment of inflammatory disorders |
US8119647B2 (en) * | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
CN101628913B (zh) * | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
US8680108B2 (en) * | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
JP2013531687A (ja) | 2010-07-16 | 2013-08-08 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリジン化合物 |
US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
BR112014004971B1 (pt) | 2011-09-02 | 2021-02-09 | Incyte Holdings Corporation | compostos heterociclilaminas, sua composição farmacêutica e seus usos |
US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
JP6014154B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
WO2013115884A2 (en) * | 2011-11-15 | 2013-08-08 | Trustees Of Boston University | Pyridopyrimidinone inhibitors of viruses |
US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
WO2013177224A1 (en) * | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
WO2014008458A2 (en) * | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
UA120353C2 (uk) * | 2013-09-10 | 2019-11-25 | Хромоселл Корпорейшн | Модулятори натрієвого каналу для лікування болю і діабету |
PE20161247A1 (es) | 2013-11-27 | 2016-11-30 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
CR20170462A (es) * | 2015-04-15 | 2018-02-01 | Hoffmann La Roche | Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
CA2986045A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
EP3310441B1 (en) | 2015-06-18 | 2020-07-29 | 89Bio Ltd. | 1, 4-substituted piperidine derivatives |
WO2016205590A1 (en) | 2015-06-18 | 2016-12-22 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック, インコーポレイテッド | 治療化合物及びその使用方法 |
PE20181003A1 (es) | 2015-09-28 | 2018-06-26 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
WO2017091592A1 (en) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
RU2019114964A (ru) | 2016-10-17 | 2020-11-17 | Дженентек, Инк. | Терапевтические средства и способы их применения |
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
WO2019236694A1 (en) * | 2018-06-05 | 2019-12-12 | Incarda Therapeutics, Inc. | Methods for diagnosing brugada syndrome using an aerosol |
CA3161008A1 (en) * | 2019-11-25 | 2021-06-03 | Amgen Inc. | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
CN110818709B (zh) * | 2019-11-28 | 2022-09-02 | 成都大学 | 一种co2参与下合成嘧啶酮类化合物的方法 |
CN113292557B (zh) * | 2021-05-31 | 2022-02-11 | 贵州大学 | 一种含吲哚单元的吡啶并嘧啶酮类介离子衍生物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63112566A (ja) * | 1986-10-28 | 1988-05-17 | Nissan Chem Ind Ltd | ピリミジノン誘導体、その製法および殺虫・殺ダニ・殺菌剤 |
AU2004285452A1 (en) * | 2003-10-21 | 2005-05-12 | Merck & Co., Inc. | Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain |
AR053713A1 (es) * | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
DE602006015658D1 (de) * | 2005-06-27 | 2010-09-02 | Amgen Inc | Entzündungshemmende arylnitrilverbindungen |
CA2622639C (en) * | 2005-10-04 | 2012-01-03 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | Hiv integrase inhibitors |
EP1818058A3 (en) * | 2006-02-13 | 2007-11-07 | Astion Pharma A/S | Treatment of mmp-mediated dermatological diseases with pemirolast |
-
2008
- 2008-02-05 MX MX2009008338A patent/MX2009008338A/es unknown
- 2008-02-05 US US12/026,435 patent/US20080194616A1/en not_active Abandoned
- 2008-02-05 RU RU2009133336/04A patent/RU2009133336A/ru unknown
- 2008-02-05 AU AU2008213836A patent/AU2008213836A1/en not_active Abandoned
- 2008-02-05 CL CL200800369A patent/CL2008000369A1/es unknown
- 2008-02-05 CA CA002677493A patent/CA2677493A1/en not_active Abandoned
- 2008-02-05 EP EP08729067A patent/EP2079737A1/en not_active Withdrawn
- 2008-02-05 WO PCT/US2008/053075 patent/WO2008097991A1/en active Application Filing
- 2008-02-05 BR BRPI0807351-1A patent/BRPI0807351A2/pt not_active IP Right Cessation
- 2008-02-05 TW TW097104675A patent/TW200838539A/zh unknown
- 2008-02-05 JP JP2009548501A patent/JP2010518026A/ja not_active Withdrawn
- 2008-02-05 AR ARP080100493A patent/AR065194A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR065194A1 (es) | 2009-05-20 |
RU2009133336A (ru) | 2011-03-20 |
US20080194616A1 (en) | 2008-08-14 |
EP2079737A1 (en) | 2009-07-22 |
AU2008213836A1 (en) | 2008-08-14 |
CL2008000369A1 (es) | 2008-04-18 |
TW200838539A (en) | 2008-10-01 |
CA2677493A1 (en) | 2008-08-14 |
WO2008097991A1 (en) | 2008-08-14 |
JP2010518026A (ja) | 2010-05-27 |
BRPI0807351A2 (pt) | 2014-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008338A (es) | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio. | |
WO2008094909A3 (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
WO2008147864A3 (en) | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions | |
JO3032B1 (ar) | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. | |
MY145694A (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
WO2008046087A3 (en) | Spiro compounds and their uses as therapeutic agents | |
MX2009010083A (es) | Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro. | |
PH12015502323A1 (en) | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents | |
MY158766A (en) | Spiro-oxindole compounds and their uses as therapeutic agents | |
MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
MX2009012168A (es) | Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta. | |
GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
TW200716596A (en) | Substituted amide derivatives and methods of use | |
WO2008046084A3 (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
TN2012000171A1 (en) | Synthetic methods for spiro-oxindole compounds | |
WO2008151288A3 (en) | Aromatic and heteroaromatic compounds useful in treating iron disorders | |
WO2008109856A3 (en) | Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions | |
WO2010132352A3 (en) | Spiro compounds and their use as therapeutic agents | |
TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives |